PARP抑制剂他拉唑帕尼联合放射治疗局部复发性妇科癌症的I期研究。
Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.
作者信息
Lakomy David S, Urbauer Diana L, Westin Shannon N, Lin Lilie L
机构信息
Dartmouth Geisel School of Medicine, Dartmouth College, Hanover, NH, United States.
Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
出版信息
Clin Transl Radiat Oncol. 2019 Dec 28;21:56-61. doi: 10.1016/j.ctro.2019.12.005. eCollection 2020 Mar.
PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.
聚（ADP-核糖）聚合酶（PARP）抑制剂已在体外和体内研究中显示出对肿瘤细胞有放射增敏作用。这是一项I期研究，旨在确定在复发性妇科癌症女性患者中，将PARP抑制剂他拉唑帕尼与放射治疗同时使用时的安全性、耐受性和最大耐受剂量。
Zotero 插件